Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jerem...
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that man...
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced two upco...
Day One Biopharmaceuticals press release ( NASDAQ: DAWN ): Q3 GAAP EPS of -$0.53. Cash, cash equivalents and short-term investments totaled $374.3 million on September 30, 2022. Net loss totaled $37.8 million for the third quarter of 2022 compared to $19.2 million for ...
Topline results for full pivotal FIREFLY-1 study population with tovorafenib (DAY101) in relapsed or progressive pediatric low-grade glioma (pLGG) are expected in the first quarter of 2023 Strengthened leadership team with key appointments to senior management team and board of direct...
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that it ...
Palm Beach, FL –– October 12, 2022 – FinancialNewsMedia.com News Commentary – The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth in several worldwide markets. The COVID-19 pandemic has impacted the who...
SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the app...
Summary Day One Biopharmaceuticals declared strong data in relapsed glioma in June. The company has strong cash position. They may submit an NDA next year. Day One Biopharmaceuticals, Inc. ( DAWN ) is a developer of targeted cancer therapies for a variety of tumo...
Day One Biopharmaceuticals press release ( NASDAQ: DAWN ): Q2 GAAP EPS of -$0.60. Cash, cash equivalents and short-term investments totaled $394.9 million on June 30, 2022. Based on current operating plan, management believes it has sufficient capital resources to fund ant...
News, Short Squeeze, Breakout and More Instantly...
Day One Biopharmaceuticals Inc. Company Name:
DAWN Stock Symbol:
NASDAQ Market:
Day One Biopharmaceuticals Inc. Website:
2024-07-20 21:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-10 18:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-08 09:30:06 ET Piper Sandler analyst issues OVERWEIGHT recommendation for DAWN on July 8, 2024 07:54AM ET. The previous analyst recommendation was Overweight. DAWN was trading at $13.71 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...